wadegarret
14 minutes ago
NMRA- Why would anyone pay more than $2 ?
Yes, woman did better in the study, but the study didn't meet primary or secondary endpoints for treating depression- and this was only phase 1 ! Not that the stock couldn't pop on momentum players, but basically the stock is worth at